**Table S1.** Patient characteristics and ABT-199 sensitivity for the diagnostic primary acute myeloid leukemia patient samples and non-malignant samples

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Patient | Gender | Age (year) | FAB subtype | WBC (x103/μL) | Blast purity (%) | Cytogenetics | Fusion gene/Gene mutation | ABT-199 IC50 (nM) |
| AML1001 | Female | 43 | M2 | 93.99 | 91 | 46, XX | None | 12138 |
| AML1002 | Male | 52 | M2 | 8.84 | 26.5 | 46, XY, t(11;15;17)(q25;q15;q21) | None | 14270 |
| AML1003 | Male | 17 | M2 | 12.94 | 68.5 | 46, XY | CEBPA | 1075 |
| AML1004 | Female | 76 | M5 | 13.93 | 84.5 | 46, XX | dupMLL, CEBPA | 19255 |
| AML1005 | Male | 52 | M4 | 34.94 | 96 | 46, XY | DEK-CAN | 11630 |
| AML1006 | Male | 43 | M2 | 31.7 | 48 | 46, XY, t(8;21)(q22;q22) | AML1-ETO | 638 |
| AML1007 | Male | 27 | M3 | 251.96 | 90.5 | 46, XY, t(15;17)(q22;q21) | PML-RARα | 5204 |
| AML1008 | Male | 59 | M2 | 254.84 | 82 | 46, XY | HOX11 | 369 |
| AML1009 | Female | 48 | M6 | 72.1 | 39 | 45, XX, del(3q), -7 | None | 1656 |
| AML1010 | Female | 35 | M2 | 10.16 | 22.5 | 45, X, -X, t(8;21)(q22;q22) | AML1-ETO, FLT3-ITD | 6729 |
| AML1011 | Female | 64 | M4 | 252.77 | 91 | Not available | dupMLL, FLT3-ITD, IDH1 | 753 |
| AML1012 | Female | 50 | M4 | 126.72 | 91.5 | 46, XX | FLT3-ITD, NPM1, DNMT3A | 4208 |
| AML1013 | Male | 69 | M5 | 222.2 | 97 | 46, XY | None | 10420 |
| AML1014 | Male | 47 | M2 | 11.13 | 80 | 46, XY | HOX11 | 6748 |
| AML1015 | Female | 59 | M4 | 31.39 | 82 | 46, XX | CEBPA | 524 |
| Non-malignant1 | Female | 51 | NA | 4.4 | NA | ND | ND | 19600 |
| Non-malignant2 | Female | 31 | NA | 4.9 | NA | ND | ND | 12710 |

Abbreviations: ND, not determined; NA, not applicable